These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 24987146)

  • 1. Human cancer growth and therapy in immunodeficient mouse models.
    Shultz LD; Goodwin N; Ishikawa F; Hosur V; Lyons BL; Greiner DL
    Cold Spring Harb Protoc; 2014 Jul; 2014(7):694-708. PubMed ID: 24987146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
    Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer.
    Maykel J; Liu JH; Li H; Shultz LD; Greiner DL; Houghton J
    Dig Dis Sci; 2014 Jun; 59(6):1169-79. PubMed ID: 24798995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced development of functional human NK cells in NOD-scid-IL2rg
    Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
    FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
    Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
    Covassin L; Jangalwe S; Jouvet N; Laning J; Burzenski L; Shultz LD; Brehm MA
    Clin Exp Immunol; 2013 Dec; 174(3):372-88. PubMed ID: 23869841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanized Mouse Models of Clinical Disease.
    Walsh NC; Kenney LL; Jangalwe S; Aryee KE; Greiner DL; Brehm MA; Shultz LD
    Annu Rev Pathol; 2017 Jan; 12():187-215. PubMed ID: 27959627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of Immunodeficient Mice Bearing Human Immune Systems by the Engraftment of Hematopoietic Stem Cells.
    Hasgur S; Aryee KE; Shultz LD; Greiner DL; Brehm MA
    Methods Mol Biol; 2016; 1438():67-78. PubMed ID: 27150084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.
    Ishikawa F; Yasukawa M; Lyons B; Yoshida S; Miyamoto T; Yoshimoto G; Watanabe T; Akashi K; Shultz LD; Harada M
    Blood; 2005 Sep; 106(5):1565-73. PubMed ID: 15920010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice.
    Bernstein JM; Brooks SP; Lehman HK; Pope L; Sands A; Shultz LD; Bankert RB
    Ann Otol Rhinol Laryngol; 2009 Dec; 118(12):866-75. PubMed ID: 20112521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
    Verma B; Wesa A
    Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice.
    Brehm MA; Bortell R; Diiorio P; Leif J; Laning J; Cuthbert A; Yang C; Herlihy M; Burzenski L; Gott B; Foreman O; Powers AC; Greiner DL; Shultz LD
    Diabetes; 2010 Sep; 59(9):2265-70. PubMed ID: 20570944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell lines.
    Kanaji N; Tadokoro A; Susaki K; Yokokura S; Ohmichi K; Haba R; Watanabe N; Bandoh S; Ishii T; Dobashi H; Matsunaga T
    Cancer Manag Res; 2014; 6():431-6. PubMed ID: 25364273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Immunodeficient Rats With Rag1 and Il2rg Gene Deletions and Human Tissue Grafting Models.
    Ménoret S; Ouisse LH; Tesson L; Delbos F; Garnier D; Remy S; Usal C; Concordet JP; Giovannangeli C; Chenouard V; Brusselle L; Merieau E; Nerrière-Daguin V; Duteille F; Bellier-Waast F; Fraichard A; Nguyen TH; Anegon I
    Transplantation; 2018 Aug; 102(8):1271-1278. PubMed ID: 29688994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engraftment of human HSCs in nonirradiated newborn NOD-scid IL2rγ null mice is enhanced by transgenic expression of membrane-bound human SCF.
    Brehm MA; Racki WJ; Leif J; Burzenski L; Hosur V; Wetmore A; Gott B; Herlihy M; Ignotz R; Dunn R; Shultz LD; Greiner DL
    Blood; 2012 Mar; 119(12):2778-88. PubMed ID: 22246028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation.
    Brehm MA; Cuthbert A; Yang C; Miller DM; DiIorio P; Laning J; Burzenski L; Gott B; Foreman O; Kavirayani A; Herlihy M; Rossini AA; Shultz LD; Greiner DL
    Clin Immunol; 2010 Apr; 135(1):84-98. PubMed ID: 20096637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments.
    Ye W; Jiang Z; Li GX; Xiao Y; Lin S; Lai Y; Wang S; Li B; Jia B; Li Y; Huang ZL; Li J; Feng F; Li S; Yao H; Liu Z; Cao S; Xu L; Li Y; Wu D; Zeng L; Zhong M; Liu P; Wen ZS; Xu B; Yao Y; Pei D; Li P
    J Hematol Oncol; 2015 May; 8():59. PubMed ID: 26022250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse.
    Fujii E; Suzuki M; Matsubara K; Watanabe M; Chen YJ; Adachi K; Ohnishi Y; Tanigawa M; Tsuchiya M; Tamaoki N
    Pathol Int; 2008 Sep; 58(9):559-67. PubMed ID: 18801070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.
    Marín-Jiménez JA; Capasso A; Lewis MS; Bagby SM; Hartman SJ; Shulman J; Navarro NM; Yu H; Rivard CJ; Wang X; Barkow JC; Geng D; Kar A; Yingst A; Tufa DM; Dolan JT; Blatchford PJ; Freed BM; Torres RM; Davila E; Slansky JE; Pelanda R; Eckhardt SG; Messersmith WA; Diamond JR; Lieu CH; Verneris MR; Wang JH; Kiseljak-Vassiliades K; Pitts TM; Lang J
    Front Immunol; 2021; 12():607282. PubMed ID: 33854497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.
    Ghosn S; Chamat S; Prieur E; Stephan A; Druilhe P; Bouharoun-Tayoun H
    Front Immunol; 2018; 9():601. PubMed ID: 29628927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.